source
- Cytokinetics aims for broader Myqorzo approval next year after supportive trial dataCytokinetics reported new data on its cardiac therapy Myqorzo, presented at a European scientific meeting. The results reinforce the drug’s efficacy in a specific heart muscle disorder. The compan…
- Daiichi Sankyo to restructure its commercial organization, appointing Ken Keller as chief commercialization officerDaiichi Sankyo announced plans to overhaul its commercial operations, with a split of its commercialization activities slated for April 1, 2027. The company has appointed veteran executive Ken Kel…